Life Sciences Tools and Services
Company Overview of Celerion Inc.
Celerion Inc. provides early clinical pharmacology research services for pharmaceutical and biotechnology companies in the United States and internationally. The company focuses on delivering applied translational medicine to support early drug development decisions. Its services include global clinical research (Phase I and IIa, and NDA-enabling clinical pharmacology study conduct); clinical pharmacology sciences (modeling and simulation, study design and protocol development, clinical data sciences, biostatistics, pharmacokinetics/pharmacodynamics (PK/PD), and medical writing and reporting); global bioanalytical services (discovery to late stage services with capabilities in small and larg...
621 Rose Street
Lincoln, NE 68502
Founded in 2010
Key Executives for Celerion Inc.
Chief Executive officer and President
Chief Cardiologist and Global Medical Director of Cardiac Safety Services
Vice President of Global Business Development
Vice President of Global Bioanalytical Services
Compensation as of Fiscal Year 2015.
Celerion Inc. Key Developments
Celerion Expands Ophthalmological Capabilities to Patient Populations in Collaboration with Queen's University, Belfast
Sep 30 14
Celerion, announced the expansion of ophthalmological services in the Belfast, Northern Ireland UK facility, by building on the successful relationship with Queen's University in Belfast. Celerion will expand its collaboration with Queen's University for access to patient populations, specialized procedures and their scientific expertise in this area. This new focus will enable Celerion to apply expertise acquired from several years of performing precise ophthalmologic measurements as part of assessing the safety of new drug candidates. By moving beyond clinical safety assessment, Celerion scientists and colleagues at The Centre for Experimental Medicine at Queen's University can perform assessments of drug effect in a controlled research environment. The focus will be on patients with eye diseases such as diabetic retinopathy, age-related macular degeneration, glaucoma, and retinal vein occlusions.
Celerion Appoints Robert Lester as Chief Cardiologist, Global Medical Director of Cardiac Safety Services
Jun 16 14
Celerion announced the appointment of Robert Lester MD FACC, as Chief Cardiologist, Global Medical Director of Cardiac Safety Services. Dr. Lester will develop and lead Celerion's strategic vision in Cardiac Safety Services. He will be based in the facility in Phoenix, Arizona. Dr. Lester comes to Celerion with over 25 years experience in clinical medicine and academia, as well as over 13 years experience as a Director and Senior Cardiologist at several Contract Research Organizations (CROs) and ECG Core labs. Dr. Lester will utilize his extensive experience and expertise in the area of cardiac safety, to provide advice and lead client programs. He will also be a driving force for Celerion's innovative Highly Automated ECG Core Lab that enables clients to expedite ECG review, thereby significantly reducing the time and cost for cardiac safety studies over traditional approaches.
Foundation for the National Institutes of Health Selects Celerion to Provide Clinical Recruitment and Conduct to Support the Beta Cell Project
Jun 11 14
Celerion announced that it has been selected by the Foundation for the National Institutes of Health (FNIH) Biomarkers Consortium to provide clinical support for The Beta Cell Project. The Beta Cell Project is a program of studies designed to standardize biomarker measures of beta cell function. Celerion will provide clinical recruitment and conduct to support The Beta Cell Project and assist the FNIH in developing pharmacodynamic measures of beta cell function, with the goal to create industry standards.
Similar Private Companies By Industry
Recent Private Companies Transactions
October 29, 2014